An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Plain-language summary

This is an exploratory sub-study investigating treatment sensitivity and prognostic factors, comparing mFOLFOX6 + Bevacizumab with mFOLFOX6 + Panitumumab in patients with previously untreated, unresectable advanced or recurrent colorectal cancer. Participants are patients already enrolled in the main study who additionally consented to this sub-study. It is a study with no assigned phase and is currently active but not recruiting new participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

Takeda

Intervention

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab

Start date

5/29/2015

Estimated completion

9/30/2027

Countries

Japan

Related genes

Locations

• Ichinomiya, Japan
• Komaki, Japan
• Kounan, Japan
• Nagakute, Japan
• Nagoya, Japan
• Okazaki, Japan
• Toyohashi, Japan
• Toyokawa, Japan
• Toyota, Japan
• Yatomi, Japan
• Daisen, Japan
• Hirosaki, Japan
• Misawa, Japan
• Kashiwa, Japan
• Yachiyo, Japan
• Matsuyama, Japan
• Tōon, Japan
• Tsuruga, Japan
• Yoshida, Japan
• Kitakyushu, Japan
• Koga, Japan
• Koga, Japan
• Kurume, Japan
• Omuta, Japan
• Aizu-Wakamatsu, Japan
• Iwaki, Japan
• Kōriyama, Japan
• Shirakawa, Japan
• Hashima, Japan
• Kakamigahara, Japan
• Minokamo, Japan
• Okazai, Japan
• Ōgaki, Japan
• Maebashi, Japan
• Ōta, Japan
• Fukuyama, Japan
• Hakodate, Japan
• Kitami, Japan
• Kushiro, Japan
• Obihiro, Japan

+111

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

(1) Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study

Exclusion Criteria:

(1) Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study